Skip to main content
< Back
About
About the conference
App
Organisers & Partners
Latest updates
Press room
Registration
Venue 22
About the venue
Rooms
Call for abstracts
Programme 22
Tracks 22
Speakers 22
Side events 22
Subscribe
days
hours
minutes
seconds
Mental health
Sessions
Wednesday, 23 November
10:50
Gambling Research
10:50
to
12:20
Insights zone 3 (I3)
Oral presentation session
Prescription opioids and overdose deaths
10:50
to
12:20
Knowledge market 1 (K1)
Structured session
Reaching out
10:50
to
12:20
Networking zone 4 (N4)
Short communication session
Substance use, mental health and mental well-being: observations, interventions and recovery promotion
10:50
to
12:20
Networking zone 3 (N3)
Short communication session
Substance-induced psychosis: register-linkage research in Nordic countries
10:50
to
12:20
Knowledge market 2 (K2)
Structured session
13:20
Special at-risk populations and need for diversified interventions to prevent overdoses: insights from the US and Europe, on fentanyl, suicidal overdoses and deaths among teen-agers
13:20
to
14:50
Central square 4 (C4)
Structured session
15:00
Convergence in behavioural addictions
15:00
to
16:30
Main stage
Structured session
Substance use and mental health disorders in Europe: prevalence, models of care, and implementation in a challenging COVID-19 context
15:00
to
16:30
Knowledge market 2 (K2)
Structured session
Understanding relationships between substance use, mental health and mental illness: Session 1
15:00
to
16:30
Networking zone 2 (N2)
e-poster guided tour
16:50
Addiction and comorbidity over the lifespan: mechanisms and interventions
16:50
to
18:20
Central square 2 (C2)
Structured session
Impact and lessons learned in implementing and sustaining Needs-Based Planning models for substance use and mental health services and systems
16:50
to
18:20
Knowledge market 2 (K2)
Structured session
18:30
Psychedelic-assisted treatment for substance use disorders – long overlooked or now overhyped?
18:30
to
19:30
Main stage
Big debate
Thursday, 24 November
09:00
Re-imagine recovery
09:00
to
10:30
Main stage
Plenary session
10:50
Neurology and neuropsychology
10:50
to
12:20
Central square 3 (C3)
Oral presentation session
Substance use and trauma
10:50
to
12:20
Knowledge market 2 (K2)
Oral presentation session
13:20
Cannabis and tobacco co-use: A ‘joint’ challenge for research and practice
13:20
to
14:50
Knowledge market 1 (K1)
Structured session
Childhood risk factors in substance use and mental health
13:20
to
14:50
Knowledge market 2 (K2)
Oral presentation session
15:00
A global symposium on the renaissance and promise of psychedelics for mental and substance use disorder treatment
15:00
to
16:30
Main stage
Structured session
Client-centered approaches
15:00
to
16:30
Central square 3 (C3)
Oral presentation session
Drug deaths: A social, structural and systems analysis
15:00
to
16:30
Knowledge market 1 (K1)
Structured session
Preventions interventions
15:00
to
16:30
Insights zone 2 (I2)
Oral presentation session
Substance use and mental health during COVID-19
15:00
to
16:30
Knowledge market 2 (K2)
Oral presentation session
Understanding relationships between substance use, mental health and mental illness: Session 2
15:00
to
16:30
Networking zone 2 (N2)
e-poster guided tour
16:50
Informing and delivering treatment
16:50
to
18:20
Networking zone 3 (N3)
Short communication session
Substance use, suicide and self-harm: epidemiology and prevention
16:50
to
18:20
Main stage
Structured session
18:30
Addiction, compulsive behaviours and unhealthy habits - A common aetiology and implications for practice?
18:30
to
19:30
Main stage
Big debate
Friday, 25 November
10:50
Associations of alcohol and substance use with mental health
10:50
to
12:20
Knowledge market 2 (K2)
Structured session
Substance use and prison
10:50
to
12:20
Central square 1 (C1)
Oral presentation session
13:20
Stress and Addiction: Updates on the Chicken or Egg question
13:20
to
14:50
Central square 4 (C4)
Structured session
Substance use, mental health risk and suicide
13:20
to
14:50
Knowledge market 2 (K2)
Oral presentation session
Understanding drug use, risk and harm
13:20
to
14:50
Networking zone 2 (N2)
e-poster guided tour
Presentations
Wednesday, 23 November
10:50
Short communication
Association between cannabis use and mental health disorders in adolescents in Catalonia: results of a cohort study
10:50
to
12:20
Networking zone 3 (N3)
Regina Muñoz-Galán
Oral presentation
3. Relapse rate of substance-induced psychosis and associated risk factors. A nationwide registerlinkage study
10:50
to
12:20
Knowledge market 2 (K2)
Heidi Taipale
Short communication
Physical activity during treatment for substance use disorder: What a systematic review tells us
10:50
to
12:20
Networking zone 3 (N3)
Florence Piché
Oral presentation
4. Substance-induced psychosis and later schizophrenia or bipolar disorder: transition rates and the role of infections
10:50
to
12:20
Knowledge market 2 (K2)
Jørgen G. Bramness
Short communication
Drug use, anxiety and depression among people living in prison in Belgium
10:50
to
12:20
Networking zone 3 (N3)
Kim Fernandez
Oral presentation
5. Antipsychotic use and associating factors among persons with substance-induced psychosis and first-episode psychosis. A nationwide register-linkage study
10:50
to
12:20
Knowledge market 2 (K2)
Jeyaniroshan Jeyapalan
Short communication
The temporal association between frequency of methamphetamine use, depression, and anxiety in a community-recruited cohort of methamphetamine smokers
10:50
to
12:20
Networking zone 3 (N3)
Zoe Duncan
Short communication
Effectiveness of mental health warnings on tobacco packaging in people with and without common mental health conditions: an online randomised experiment
10:50
to
12:20
Networking zone 3 (N3)
Katherine Sawyer
Oral presentation
1. Annual incidence of substance-induced psychoses in Scandinavia from 2000 to 2016
10:50
to
12:20
Knowledge market 2 (K2)
Eline Borger Rognli
Short communication
A realist evaluation of greenspace programmes for improving mental health and supporting people with problem substance use
10:50
to
12:20
Networking zone 3 (N3)
Wendy Masterton
Oral presentation
2. Characteristics of incident substance-induced psychosis compared to incident first episode psychosis. A nationwide register-linkage study
10:50
to
12:20
Knowledge market 2 (K2)
Pihla Sassi
Oral presentation
Characterizing habit formation in modern slot machine gambling
10:50
to
12:20
Insights zone 3 (I3)
Luke Clark
Oral presentation
A scoping review on cryptocurrency trading among young people and its association with gambling and mental health
10:50
to
12:20
Insights zone 3 (I3)
Benjamin Johnson
Oral presentation
Treatment-seeking problem gamblers: characteristics of individuals who offend to finance gambling
10:50
to
12:20
Insights zone 3 (I3)
Amanda Roberts
Oral presentation
Cue-reactivity and inhibitory control in behavioral addcitions: an overview of functional neuroimaging studies
10:50
to
12:20
Insights zone 3 (I3)
Kjell Büsche
Oral presentation
1. Characteristics of suicides among overdose deaths in Norway in 2016-2020
10:50
to
12:20
Knowledge market 1 (K1)
Hilde Marie Erøy Edvardsen
Oral presentation
2. Individuals dying of overdoses related to pharmaceutical opioids differ from individuals dying of overdoses related to other substances
10:50
to
12:20
Knowledge market 1 (K1)
Svetlana Skurtveit
Oral presentation
3. Changes in primary cause of overdose deaths following liberalisations in opioid prescription practices and differences in overdose death correlates.
10:50
to
12:20
Knowledge market 1 (K1)
Linn Gjersing
Oral presentation
4. Fatal overdoses in a cohort of chronic pain patients
10:50
to
12:20
Knowledge market 1 (K1)
Aleksi Hamina
Short communication
OurFutures: A suite of universal evidence-based eHealth programs to prevent substance use and mental ill-health among adolescents
10:50
to
12:20
Networking zone 4 (N4)
Lauren Gardner
Short communication
Telegram as a space for peer-leded harm reduction communities and netreach interventions
10:50
to
12:20
Networking zone 4 (N4)
Sara Rolando
Short communication
Collaboration between prevention work and law enforcement in a nightlife drug-using setting: a vulnerable encounter?
10:50
to
12:20
Networking zone 4 (N4)
Annemie Coone
Short communication
Addressing Adherence and Success Rates of a Digital Self-Help Intervention for Alcohol and Substance Use with Machine Learning
10:50
to
12:20
Networking zone 4 (N4)
Anna Goudriaan
Short communication
What’s trending? Using social media to engage with hard to reach groups through an online survey
10:50
to
12:20
Networking zone 4 (N4)
Nicki Killeen
Short communication
Accessability of mental health services for people with substance use: findings from the SUMHIT project
10:50
to
12:20
Networking zone 4 (N4)
Jürgen Magerman
Short communication
Drug use and associated factors in Secondary Education in Basque Country
10:50
to
12:20
Networking zone 4 (N4)
Álvaro Moro Inchaurtieta
Short communication
Mental Health and Addiction Prevention for former refugees: We do it together
10:50
to
12:20
Networking zone 3 (N3)
Jannet De Jonge
Short communication
What aspects of a drug checking service are important in a high-cost drug market?
10:50
to
12:20
Networking zone 4 (N4)
Raimondo Bruno
13:20
Oral presentation
3. High drug-related death mortality in Finland – special focus on young adults and teenagers
13:20
to
14:50
Central square 4 (C4)
Prikko Kriikku
Oral presentation
4. Intentional overdoses and associated mental health challenges, an overlooked sub-population of overdoses
13:20
to
14:50
Central square 4 (C4)
Thomas Clausen
Oral presentation
1. Overdose prevention and treatment implications of fentanyl use in the United States
13:20
to
14:50
Central square 4 (C4)
Alexander Walley
Oral presentation
2. Fentanyl related deaths and fentanyl acute toxicity presentations at emergency Departments in Europe, 2010-2020
13:20
to
14:50
Central square 4 (C4)
Peter Heudtlass
15:00
e-poster
Childhood trauma among patients with substance use disorder
15:00
to
16:30
Networking zone 2 (N2)
Sana Derouiche
Discussion
Discussion: Substance use and mental health disorders in Europe
15:00
to
16:30
Knowledge market 2 (K2)
Gabriele Fischer
e-poster
Association between Tramadol use disorder and depressive disorder in Oran, northwest of Algeria.
15:00
to
16:30
Networking zone 2 (N2)
Amel Kherraf
e-poster
Bridging the Gap in Violence Prevention and Mental Health Support through Culturally Relevant Community-Led Initiatives.
15:00
to
16:30
Networking zone 2 (N2)
Rita Gatonye
e-poster
A systematic review and meta-analyses of longitudinal studies on mood and anxiety symptoms following prescription opioid use.
15:00
to
16:30
Networking zone 2 (N2)
Janni Leung
e-poster
Vicarious trauma among nurses working in addiction services and the role of leadership: a European mixed methods study
15:00
to
16:30
Networking zone 2 (N2)
K. Nicki Annunziata
e-poster
Pharmacological treatment of the concurrence of substance use disorder and another mental disorder in Spain. Results of a national survey.
15:00
to
16:30
Networking zone 2 (N2)
Juan J. Fernández-Miranda
e-poster
Influence of gender on the prevalence and pharmacological treatment of the co-occurrence of substance use disorder and another mental disorder in Spain.
15:00
to
16:30
Networking zone 2 (N2)
Silvia Díaz-Fernández
Oral presentation
1. What do we mean by psychiatric comorbidity or dual disorders?
15:00
to
16:30
Knowledge market 2 (K2)
Marta Torrens
e-poster
Cognitive screening for long term substance use outcome in a cohort of patients with polysubstance use disorder
15:00
to
16:30
Networking zone 2 (N2)
Jens Hetland
Oral presentation
2. Impact of Covid19 on mental health and drug use: main findings from the EMCDDA trendspotter study
15:00
to
16:30
Knowledge market 2 (K2)
Franca Beccaria
e-poster
Anhedonia during recovery of polysubstance use
15:00
to
16:30
Networking zone 2 (N2)
Aleksander Erga
Oral presentation
3. Psychiatric comorbidity in the European countries: prevalence and models of care
15:00
to
16:30
Knowledge market 2 (K2)
Francina Fonseca
e-poster
COVID-19 pandemic induces severe impact on substances administration and on aspects of psychosocial life of patients under methadone and buprenorphine maintenance treatment
15:00
to
16:30
Networking zone 2 (N2)
Vasilios Stavropoulos
Oral presentation
4. The dual diagnosis inpatient and outpatient treatment program in Ljubljana: practical implementatio
15:00
to
16:30
Knowledge market 2 (K2)
Nusa Segrec,
Andrej Kastelic
Oral presentation
2. Convergences in the neurobiology of behavioral addictions
15:00
to
16:30
Main stage
Marc N. Potenza
Oral presentation
3. Convergences in the treatment of behavioral addictions
15:00
to
16:30
Main stage
Susana Jiménez-Murcia,
Fernando Fernández-Aranda,
Roser Granero
Oral presentation
4. Convergences in behavioral addiction policies
15:00
to
16:30
Main stage
Sophia Achab
Oral presentation
1. Convergences in the psychology of behavioral addictions
15:00
to
16:30
Main stage
Matthias Brand
Discussion
Convergence in behavioural addictions
15:00
to
16:30
Main stage
Luke Clark
Oral presentation
0. Convergence in behavioural addictions: Introduction
15:00
to
16:30
Main stage
Zsolt Demetrovics
16:50
Oral presentation
2. Impact and lessons learned in the implementation of a NBP model across the province of Quebec, Canada
16:50
to
18:20
Knowledge market 2 (K2)
Joël Tremblay
Oral presentation
1. Implementation of a substance use NBP model in a Northern Region of Ontario- results and lessons learned
16:50
to
18:20
Knowledge market 2 (K2)
Stephanie Paquette
Oral presentation
1. First findings of an RCT on treatment of PTSD in addiction: simultaneous or sequential treatment with EMDR, Prolonged Exposure, Imaginary Rescripting
16:50
to
18:20
Central square 2 (C2)
Nathalie Faber
Oral presentation
3. Development and pilot testing an integrated mental health and substance use Needs-based Planning model: Lessons learned for local planning and model refinements
16:50
to
18:20
Knowledge market 2 (K2)
Brian Rush
Oral presentation
2. Older adults and alcohol use: negative affect, resilience, and alcohol use as interacting factors
16:50
to
18:20
Central square 2 (C2)
Yannick van Gils
Oral presentation
5. Focus on implementation processes, impacts to date and pros and cons of the sustainability of the Australian Mental Health model
16:50
to
18:20
Knowledge market 2 (K2)
Sandra Diminic
Oral presentation
3. Effectiveness of a digital alcohol moderation intervention as an add-on to depression treatment for young adults: findings of a pragmatic randomized controlled trial
16:50
to
18:20
Central square 2 (C2)
Maria J.E. Schouten
Oral presentation
4. Focus on implementation processes, impacts to date and pros and cons of the sustainability of the Auralian SU model model
16:50
to
18:20
Knowledge market 2 (K2)
Alison Ritter
Oral presentation
4. Illegal substance use during pregnancy: what do we know about risks and detoxification?
16:50
to
18:20
Central square 2 (C2)
Cleo L. Crunelle
Discussion
Strategic approach to service prioritization and resource allocation
16:50
to
18:20
Knowledge market 2 (K2)
Daniel Vigo
18:30
Discussion
Debating psychedelic-assisted treatment for substance use disorders – long overlooked or now overhyped?
18:30
to
19:30
Main stage
Tomáš Páleníček,
Andrea Jungaberle,
John Marsden,
Gabriella Gobbi
Thursday, 24 November
09:00
Keynote presentation
Addiction Recovery: From Culture to Science
09:00
to
10:30
Main stage
John F. Kelly
Keynote presentation
One should not have to recover alone
09:00
to
10:30
Main stage
Charlotte Colman
Keynote presentation
Introduction to Treatment and Recovery Systems: England as a case example
09:00
to
10:30
Main stage
Ed Day
10:50
Oral presentation
The association between moral injury and cannabis use disorder among Israeli combat veterans: current state of knowledge and future directions
10:50
to
12:20
Knowledge market 2 (K2)
Daniel Feingold
Oral presentation
Alcohol and drug use among trauma patients with injuries of violence– results from the IDART study
10:50
to
12:20
Knowledge market 2 (K2)
Benedicte Jørgenrud
Oral presentation
addictive disorders and post-traumatic stress disorders
10:50
to
12:20
Knowledge market 2 (K2)
Léa Montagnier
Oral presentation
A novel trauma-focused psychological therapy for co-occurring substance use and PTSD among adolescents
10:50
to
12:20
Knowledge market 2 (K2)
Emma Barrett
Oral presentation
Mental health and associations with tobacco smoking and quitting behaviour in the population of Germany
10:50
to
12:20
Central square 3 (C3)
Sabrina Kastaun
Oral presentation
Neuropsychology of Addictions in Therapeutic Communities: assessing and understanding cognitive recovery through a residential treatment of substance use disorders
10:50
to
12:20
Central square 3 (C3)
Simon Deniel
Oral presentation
Binge alcohol intake triggers microglial activation and TNF-dependent aberrant synaptic pruning, causing synapse loss and increased anxiety
10:50
to
12:20
Central square 3 (C3)
Teresa Summavielle
Oral presentation
High dose anabolic steroid use and facial emotion recognition, the hormonal influence on social cognition.
10:50
to
12:20
Central square 3 (C3)
Astrid Bjørnebekk
13:20
Oral presentation
The Role of Adverse Childhood Experiences (ACEs) on People in Opiate Agonist Treatment: The importance of feeling unloved
13:20
to
14:50
Knowledge market 2 (K2)
David McDonagh
Oral presentation
Longitudinal patterns of problematic cannabis use in adolescence and their association with childhood psychological risk factors
13:20
to
14:50
Knowledge market 2 (K2)
Rachel Lees
Oral presentation
Childhood maltreatment and alcohol problems in young adulthood: coping style as a mediator and potential intervention target.
13:20
to
14:50
Knowledge market 2 (K2)
Lucinda Grummitt
Oral presentation
Exploring the link between childhood maltreatment and substance use disorder using a prospective, genetically informative and experimental approach
13:20
to
14:50
Knowledge market 2 (K2)
Andrea Johansson Capusan
Oral presentation
1. Association of cannabis and tobacco use with incident anxiety, mood and psychotic disorders: a systematic review
13:20
to
14:50
Knowledge market 1 (K1)
Chloe Burke
Oral presentation
3. The Cannabis And Tobacco Cessation Advice (CATCA) project: A mixed method study exploring UK stop smoking practitioners’ knowledge, attitudes and practices around co-use
13:20
to
14:50
Knowledge market 1 (K1)
Maria Duaso
Oral presentation
4. Changes in tobacco use among people with cannabis use disorder treated in programs
13:20
to
14:50
Knowledge market 1 (K1)
Cristina Martínez
Oral presentation
2. Quitting experiences, attitudes and beliefs amongst UK young adult co-smokers: A qualitative interview study
13:20
to
14:50
Knowledge market 1 (K1)
Hannah Walsh
15:00
Oral presentation
Quality management in prevention of risk behaviors in school setting: a Case study from Czech republic
15:00
to
16:30
Insights zone 2 (I2)
Elizabeth Novakova
Oral presentation
Durability of anxiety, depression, and substance use prevention effects from teenage years to young adulthood: 6-year outcomes from a school-based cluster randomised controlled trial delivered in adolescence.
15:00
to
16:30
Insights zone 2 (I2)
Zachary Bryant
Oral presentation
The 7-year effectiveness of school-based alcohol use prevention from adolescence to early adulthood: An RCT of universal, selective and combined interventions.
15:00
to
16:30
Insights zone 2 (I2)
Nicola Newton
Oral presentation
Design and Evaluation of a neuroscience-based, harm reduction program to prevent alcohol and illicit substance use among late adolescents: An RCT of the Illicit Project
15:00
to
16:30
Insights zone 2 (I2)
Emily Stockings
Oral presentation
The role of place-making dynamics in recovery from co-occurring disorders: An in-depth ethnographic study
15:00
to
16:30
Knowledge market 2 (K2)
Clara De Ruysscher
e-poster
Program 'Eu e os Outros': Adaptation to the university context
15:00
to
16:30
Networking zone 2 (N2)
Mariana Montalvão
e-poster
Perception of the risk associated with drug use in patients with a previous episode of Cannabis-Induced Psychotic Disorder
15:00
to
16:30
Networking zone 2 (N2)
Maria Coelho
e-poster
Khat and neurobehavioral functions: a systematic review
15:00
to
16:30
Networking zone 2 (N2)
Manuel Jesús Ruiz Muñoz
e-poster
Group Intervention for Parents of People With Psychotic and Substance Use Disorders: A Qualitative Evaluation of appropriateness
15:00
to
16:30
Networking zone 2 (N2)
Karine Gaudreault
e-poster
How Attention Deficit Hyperactivity Disorder and Substance Use Disorder influence each other: A non-systematic literature review
15:00
to
16:30
Networking zone 2 (N2)
Catarina Oliveira
e-poster
Antisocial personality disorder: A high risk of polydrug use?
15:00
to
16:30
Networking zone 2 (N2)
Ayoub Salhi
e-poster
Prescription Patterns on Patients with Dual Diagnosis: A Retrospective Inpatient Analysis
15:00
to
16:30
Networking zone 2 (N2)
Inês Pereira
e-poster
The war on time: an insight into the temporal relation between cannabis consumption and toxic psychosis
15:00
to
16:30
Networking zone 2 (N2)
Ana Soares
e-poster
Smoking-related health inequalities, tobacco smoking and substance use disorder.
15:00
to
16:30
Networking zone 2 (N2)
Mireia Graell Gabriel
Oral presentation
Changes in mental health among drug users during Covid-19. Evidence from a repeated cross-sectional survey in Belgium
15:00
to
16:30
Knowledge market 2 (K2)
Elena Damian
e-poster
Substance-Related Problems in Adolescents with ADHD-Diagnoses: The Importance of Self-Reported Conduct Problems
15:00
to
16:30
Networking zone 2 (N2)
Ove Heradstveit
Oral presentation
Online peer support for concurring mental health and addiction problems during the Covid19 pandemic: feeling of group inclusion and perceived effectiveness.
15:00
to
16:30
Knowledge market 2 (K2)
Raffaella Milani
Oral presentation
5. Drug Policy and The Rise and Decline of Racial Stratification of Prescribing and Overdose Mortality
15:00
to
16:30
Knowledge market 1 (K1)
Brian Kelly
Oral presentation
1. Drug-related deaths among young people: a social, structural and systems autopsy
15:00
to
16:30
Knowledge market 1 (K1)
Aileen O'Gorman
Oral presentation
2. Drug-related deaths in prisons in England and Wales, 2015-2020: an examination of key trends and issues for policy and practice
15:00
to
16:30
Knowledge market 1 (K1)
Karen Duke
Oral presentation
3. The role of Primary Care in the prevention of drug-related deaths: Patient and family member perspectives
15:00
to
16:30
Knowledge market 1 (K1)
Katie Colliver
Discussion
What can a social, structural and systems analysis tell us about drug-related deaths and what are the implications for policy and addiction science?
15:00
to
16:30
Knowledge market 1 (K1)
Anne Whittaker
Oral presentation
4. The role of Primary Care in the prevention of drug-related deaths: service provider perspectives
15:00
to
16:30
Knowledge market 1 (K1)
Betsy Thom
Oral presentation
1. Combining Psychedelic Treatments with Current Substance Use Disorder Treatments
15:00
to
16:30
Main stage
Johannes Thrul
Oral presentation
2. Improving the self: Psychedelic drug use and the enhancement-treatment debate
15:00
to
16:30
Main stage
Margit Anne Petersen
Oral presentation
3. Psychedelics in psychiatry: focus on evidence and mechanisms of relevance to affective disorders and addictions
15:00
to
16:30
Main stage
David Erritzoe
Oral presentation
Who is using take-home naloxone? An examination of super-savers
15:00
to
16:30
Central square 3 (C3)
Desiree Eide
Oral presentation
Examining health care from the drug user perspective: what works, what doesn't and what needs to change
15:00
to
16:30
Central square 3 (C3)
Mary Ellen Harrod
Oral presentation
An Evaluation of the Co-Design of an Anti-Stigma Training Programme
15:00
to
16:30
Central square 3 (C3)
Sonam Prakashini Banka
Oral presentation
Once you’ve addressed your drinking, we’ll address your mental health': A qualitative exploration of patient and providers’ experiences of services for co-occurring heavy drinking and depression in North East England
15:00
to
16:30
Central square 3 (C3)
Amy O'Donnell
Oral presentation
Police officers’ attitudes and practices toward harm reduction services in Sweden – a qualitative study
15:00
to
16:30
Central square 3 (C3)
Johan Nordgren
e-poster
The Clinical Course of Comorbid Substance Use Disorder and Attention Deficit/Hyperactivity Disorder: Protocol and Clinical Characteristics of the INCAS Study
15:00
to
16:30
Networking zone 2 (N2)
Johan Franck
16:50
Oral presentation
Suicide and self-harm during COVID-19 and beyond.
16:50
to
18:20
Main stage
Navneet Kapur
Oral presentation
Adolescent substance use, self-harm and suicide: Findings from the Northern Finland Birth Cohort 1986.
16:50
to
18:20
Main stage
Solja Niemelä
Oral presentation
Restricting access to means: Public health approaches to reduce drug- and alcohol-related self-harm.
16:50
to
18:20
Main stage
Eve Griffin
Short communication
Outreach for socially marginalized trimorbid veterans in Denmark – preliminary results
16:50
to
18:20
Networking zone 3 (N3)
Henrik Thiesen
Short communication
A Feasibility Study of Mentalization Based Therapy for Antisocial personality disorder with substance use disorder in Norway- preliminary findings
16:50
to
18:20
Networking zone 3 (N3)
Katharina Morken
Short communication
Working in drug treatment and health care facilities
16:50
to
18:20
Networking zone 3 (N3)
Maitena Milhet
Short communication
Incidence and determinants of CoVID-19 in patients seeking treatment of Substance Use Disorder: a population-based linkage study
16:50
to
18:20
Networking zone 3 (N3)
Irene Lana
Short communication
Perspectives Pathways and Priorities of People with Lived and Living Experience of Substance Use: Informing Policies (P5 Project YXE)
16:50
to
18:20
Networking zone 3 (N3)
Barbara Fornssler
Short communication
The Treatment of Addictions in Portugal - What Future?
16:50
to
18:20
Networking zone 3 (N3)
João Feliz
Short communication
The effect of opioid agonist therapy on mental health of PWID in Ukraine
16:50
to
18:20
Networking zone 3 (N3)
Iryna Ivanchuk
18:30
Discussion
Debating addiction, compulsive behaviours and unhealthy habits - A common aetiology and implications for practice?
18:30
to
19:30
Main stage
Zsolt Demetrovics,
Sophia Achab,
Wim van den Brink,
Fernando Fernández-Aranda
Friday, 25 November
10:50
Oral presentation
1. Socioeconomic status, alcohol use and the mediating role of social support and neighbourhood disadvantage among individuals meeting criteria for a mental health problem: a cross-sectional study
10:50
to
12:20
Knowledge market 2 (K2)
Jo-Anne Puddephatt
Oral presentation
2. The association between mental health and alcohol use in racial and ethnic groups: A secondary data analysis across studies
10:50
to
12:20
Knowledge market 2 (K2)
Laura Goodwin
Oral presentation
3. Association of psychological distress with smoking cessation, duration of smoking abstinence and use of other nicotine-containing products: A cross-sectional population survey in Great Britain
10:50
to
12:20
Knowledge market 2 (K2)
Leonie Brose
Oral presentation
4. Can we make cannabis safer? An experimental study of four CBD: THC rations in healthy volunteers
10:50
to
12:20
Knowledge market 2 (K2)
Amir Englund
Oral presentation
The Impact of Co-Occurring Mental Health Problems on Referral to and Initiation of Treatment Among Youth Under Probation Supervision
10:50
to
12:20
Central square 1 (C1)
Steven Belenko
Oral presentation
(Ex-)inmates' substance use: a needs assessment based on semi-structured interviews
10:50
to
12:20
Central square 1 (C1)
Nicky Dirkx
Oral presentation
Prevalence of heroin drug use before and during imprisonment in Europe: results from a comprehensive literature review and analysis of prevalence data in six European countries
10:50
to
12:20
Central square 1 (C1)
Sara Mazzilli
Oral presentation
Factors associated with mortality in The Norwegian Offender Mental Health and Addiction (NorMA)- cohort
10:50
to
12:20
Central square 1 (C1)
Torill Tverborgvik
Oral presentation
All cause and cause specific mortality among individuals imprisoned for driving under the influence of alcohol and drugs in Norway (2000-2016)
10:50
to
12:20
Central square 1 (C1)
Ragnhild Jamt
Discussion
Commonalities across the research on different substances
10:50
to
12:20
Knowledge market 2 (K2)
Abi Rose
13:20
Oral presentation
Implementation of a community-based psychiatric intervention among people who inject drugs in the City of Haiphong, Vietnam: the DRIVE-Mind project
13:20
to
14:50
Knowledge market 2 (K2)
Laurent Michel
Oral presentation
Hazardous, harmful and dependent alcohol use in Crisis Resolution Team patients: relationship with death or service recontact after a suicidal crisis.
13:20
to
14:50
Knowledge market 2 (K2)
John Robins
Oral presentation
Comparing characteristics of suicide to non-suicide drug poisoning, by sex, in Ireland.
13:20
to
14:50
Knowledge market 2 (K2)
Ena Lynn
Oral presentation
Characteristics associated with suicide among people who use drugs in Ireland 2015 to 2017: a repeated cross-sectional study
13:20
to
14:50
Knowledge market 2 (K2)
Suzi Lyons
Oral presentation
The impact of detoxification on suicidal behaviour among heroin users: longitudinal data from South Africa
13:20
to
14:50
Knowledge market 2 (K2)
Nirvana Morgan
Oral presentation
TitleDeterminants of psychological distress during the COVID-19 pandemic among people who use drugs in Montreal, Canada
13:20
to
14:50
Knowledge market 2 (K2)
Iuliia Makarenko
Oral presentation
Alcohol, tobacco and cannabis use and mental health as well as other associated factors during the COVID-19 pandemic among German university students
13:20
to
14:50
Knowledge market 2 (K2)
Stefanie Helmer
Oral presentation
1. Cue-induced cocaine craving enhances psychosocial stress and vice versa in chronic cocaine users
13:20
to
14:50
Central square 4 (C4)
Boris Quednow
Oral presentation
2. The endocannabinoid system and drug addiction: basal and stress-related endocannabinoid plasma levels in chronic cocaine users and prescription opioid users
13:20
to
14:50
Central square 4 (C4)
Sara Kroll
Oral presentation
3. The endocannabinoid system as a potential buffer against the development of a substance use disorder following childhood trauma exposure
13:20
to
14:50
Central square 4 (C4)
Leah M. Mayo
Oral presentation
4. Understanding the mechanisms that link childhood stress with risk of addiction
13:20
to
14:50
Central square 4 (C4)
Molly Carlyle
Oral presentation
5. Is opioid liking driven by relief or reward? Evidence from clinical and experimental studies of acute stress
13:20
to
14:50
Central square 4 (C4)
Isabell M. Meier
e-poster
How hair keeps track: Associations between hair concentrations of psychoactive substances and steroid hormones in a large cohort sample of young adults in Switzerland
13:20
to
14:50
Networking zone 2 (N2)
Lydia Johnson-Ferguson
e-poster
Changes in sexualised and non-sexualised drug use among LGBT+ people during the COVID-19 pandemic: A systematic review
13:20
to
14:50
Networking zone 2 (N2)
Dean Connolly
e-poster
Four-year long wastewater-based monitoring of illicit drug consumption pilot project in Switzerland
13:20
to
14:50
Networking zone 2 (N2)
Livia Andrani
e-poster
How are profiles of substance use linked to social function in the following seven years?
13:20
to
14:50
Networking zone 2 (N2)
Sidsel Karsberg
e-poster
A systematic review of self-report and behavioural measures of the Addiction Neuroclinical Assessment constructs of incentive salience and negative emotionality, in adults who use psychoactive drugs.
13:20
to
14:50
Networking zone 2 (N2)
Maria Bravo Aguilera
e-poster
Abuse of prescription psychoactive medicines
13:20
to
14:50
Networking zone 2 (N2)
Darja Lavtar
e-poster
Changes in substance use during the COVID-19 pandemic: Longitudinal analysis of risk behavior and mental health of MSM using HIV pre-exposure prophylaxis
13:20
to
14:50
Networking zone 2 (N2)
Babette Lea Winter
e-poster
Non-prescribed buprenorphine and reduction in illicit opioids use among individuals with opioid use disorder: a longitudinal study
13:20
to
14:50
Networking zone 2 (N2)
Raminta Daniulaityte
e-poster
Sexualized substance use, consumption motives and risk factors for relapse of addiction patients. Results of a cross-sectional study in addiction treatment facilities in Germany.
13:20
to
14:50
Networking zone 2 (N2)
Daniel Deimel
e-poster
Suicide and self-harm among people prescribed opioid agonist treatment in New South Wales: a retrospective data linkage study
13:20
to
14:50
Networking zone 2 (N2)
Samantha Colledge-Frisby